AUTHORS
Saubia Fathima, MD, Abirame Gopinath, MBBS2, Amina Akram, MBBS3, Ali Alsugair, MBBS4, Buraq Ahmed5, Priyansh Faldu6, Rania Abdelaziz7, James Foran, FRCPC8, Abhishek Avinash Mangaonkar, MBBS9, Mark R. Litzow, MD10, Hemant Murthy, MD11, Lisa Sproat, M.D.12, Jeanne Palmer, MD13, Aasiya Matin, MBBS14, Ernesto Ayala, MD15, Madiha Iqbal, MBBS, MD16, Nandita Khera, MD17, Mehrdad Hefazi Torghabeh, MD18, Saurabh Chhabra, MD, MBBS19, Kebede Begna, M.D.20, Animesh Pardanani, PhD, MBBS21, William Hogan, M.B., B.Ch.22, Mithun Shah, MD, PhD23, Naseema Gangat, MBBS24, Hassan B Alkhateeb, M.D.25, Ayalew Tefferi, MD26
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Jacksonville, Florida, United States
16 Mayo Clinic, Jacksonville, Florida, United States
17 Mayo Clinic, Phoenix, Arizona, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Phoenix, Arizona, United States
20 Mayo Clinic, Rochester, United States
21 Mayo Clinic, Rochester, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Mayo Clinic, Rochester, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States
ABSTRACT
Background:
The Dynamic International Prognostic Scoring System (DIPSS) and Mutation-enhanced International Prognostic Scoring System, version 2.0 (MIPSSv2) are often used to guide treatment decisions in primary myelofibrosis (PMF). Allogeneic stem cell transplantation (ASCT) is the only curative therapy in PMF but is associated with substantial procedure-related mortality and morbidity. Optimal timing of ASCT is, therefore, critical in order to minimize risk and maximize benefit. The current study was designed to address the issue after accounting for baseline risk of disease progression and immortal time bias associated with ASCT.
Methods:
Diagnosis and disease sub-classification were according to International Consensus Classification. Risk stratification was performed using DIPSS and MIPSSv2. Overall survival (OS) was calculated from the time of PMF diagnosis/referral to death or last follow-up. Time-dependent Cox models were used to account for ASCT as a time-dependent covariate.
Results
A total of 1036 Mayo Clinic patients with chronic phase PMF (PMF-CP) were included (66% male, median age 65 years); 202 patients (19%) underwent ASCT. Driver mutations included JAK2 (60%), CALR type 1 (19%), MPL (9%), triple negative (9%) and CALR type 2 (3%). Cytogenetic analysis was available in 1001 patients with 34% being abnormal. Additional mutation information was available in 743 patients: ASXL1 (36%), TET2 (15%), and SRSF2 (13%), being the most frequent.
At a median follow-up of 105 months, 564 (54%) deaths were documented. Median OS from diagnosis for the entire cohort (regardless of transplant status) was 83 months, with 10/20-year survival rates of 37%/19%. Median time to ASCT was 20.5 months. ASCT was associated with superior OS (median 272 vs. 70 months for non-transplanted patients; HR 0.4, 95% CI 0.3-0.5; p<0.01) with 10-/20-year survival rates of 63%/55% vs. 31%/11%. The survival advantage for ASCT was maintained after excluding patients older than age 75 years from the non-ASCT cohort (median 272 vs. 77 months; p<0.01).
DIPSS-adjusted survival comparison
Baseline DIPSS risk stratification was available for 831 patients. The distribution of ASCT/non-ASCT patients across DIPSS categories included low (42/100), intermediate-1 (67/285), intermediate-2 (50/216) and high (9/62) risk. Time from diagnosis to ASCT differed across risk categories, with longer interval in low (median 56 months) and intermidiate-1 (median 28 months), compared to intermediate-2 (median 9 months) and high (median 9 months) risk (p<0.01). Time-dependent cox models confirmed the favorable impact of ASCT in intermediate-2 (HR 0.35, 95% CI 0.2-0.6; p<0.01), and high (HR 0.1, 95% CI 0.01-0.7; p=0.02) DIPSS risk groups. Conversely, OS was inferior in patients with low-risk DIPSS who underwent ASCT (HR 1.97, 95% CI 1.0-3.7; p=0.038); ASCT did not influence OS in intermediate-1 risk group (HR 0.87, 95% CI 0.56-1.3, p=0.5).
MIPSSv2-adjusted survival comparison
Baseline MIPSSv2 risk stratification was available for 589 patients. ASCT/non-ASCT patients were categorized into very low (2/25), low (18/89), intermediate (36/106), high (68/166), and very high (19/60) MIPSSv2 risk categories. Due to small number of informative cases, MIPSSv2 “very low and low” and “high and very high” risk categories were combined for subsequent analyses. Median time to ASCT was longer in low/very low (73 months) and intermediate (33.5 months) risk, compared to high/very high (12 months; p<0.01) risk patients. In time-dependent Cox models adjusted for MIPSS70+ v2 risk category, ASCT was associated with improved OS only in high/very high-risk patients (HR 0.51, 95% CI 0.3-0.8; p<0.01).
Multivariable analysis including ASCT as a time-dependent covariate and other risk factors
In a time-dependent Cox model, MIPSSv2 low/very low and intermediate-risk, each compared to high/very high risk (HR 0.2 and 0.45, p<0.01), undergoing ASCT (HR 0.7; p=0.03), absence of progression to blast-phase (0.7, p=0.01), absolute monocyte count <1 × 109 (HR 0.6, p<0.01) and leukocyte count <11 × 109 (HR 0.7, p=0.01) were independently associated with superior OS.
Conclusion
The current, so far largest single institutional, and immortal time-adjusted study confirms the benefit of ASCT in clinically and molecularly higher risk PMF (DIPSS intermediate-2/high-risk and MIPSSv2 high/very high-risk) and also suggests a potentially negative impact in lower risk disease.
DISCLOSURES
Saubia Fathima, MD: No relevant conflicts of interest to declare.